Category: Publications
Search News
Investigating new treatment targets for lymphoma, and beyond
5th May 2022
We spoke with Dr John Riches, Clinical Senior Lecturer in the Centre for Haemato-Oncology at Barts Cancer Institute, Queen Mary University of London, about his team’s recent publication, which describes a new potential treatment target for a subset of lymphomas.
Read more
Study suggests simple blood test could help to monitor pancreatic cancer patients
28th April 2022
Researchers from Barts Cancer Institute at Queen Mary University of London have found it is possible to identify and track genetic variations in the tumours of patients with pancreatic cancer using a simple blood test.
Read more
Rewiring the biology of leukaemia cells to reverse drug resistance
20th April 2022
Researchers from Barts Cancer Institute at Queen Mary University of London have identified a way to reverse resistance to a group of cancer drugs, known as kinase inhibitors, in leukaemia cells. By rewiring the inner workings of the cancer cells, the team was able to prime leukaemia cells for sensitivity to treatment in the laboratory.
Read more
Understanding the evolution of Barrett’s oesophagus to cancer
17th February 2022
February is Oesophageal Cancer Awareness Month. At Barts Cancer Institute, Queen Mary University of London, a key area of research focus is on a condition that can precede oesophageal cancer called Barrett’s oesophagus.
Read more
Immunotherapy significantly reduces recurrence in aggressive breast cancer
10th February 2022
An immunotherapy drug called ‘pembrolizumab’ has been shown to significantly reduce disease recurrence in patients with the most aggressive type of breast cancer, according to results from a phase III clinical trial led by Professor Peter Schmid from Queen Mary University of London and Barts Health NHS Trust.
Read more
Targeting healthy cells changes invasive behaviour of pancreatic cancer
25th January 2022
Researchers from Barts Cancer Institute at Queen Mary University of London, led by Dr Angus Cameron, have found a way to modulate the invasive behaviour of pancreatic cancer by targeting a non-cancerous cell type found within pancreatic tumours. The findings, published in Cell Reports, provide valuable insights into the biology of pancreatic cancer progression, and could help to drive improvements in cancer treatment.
Read more